1. Background {#sec1}
=============

Cystic fibrosis (CF) is the most frequent life-threatening congenital disease in Caucasians. Airway colonization with pathogens like *P. aeruginosa* and *S. aureus* belongs to the primary reasons for premature death in patients with CF and antibiotic treatment is a primary reason for improvement of life expectancy within the last decades in patients treated with aggressive antimicrobial regimes \[[@B1]\]. Thereby, CF patients in middle Europe and the US did not reach school age some decades ago, and now CF patients in these countries survive for about 40 years by mean \[[@B1]\]. Therefore the question to optimize antibiotic treatment is a crucial issue in CF care and, basically, the approach of a survey on evidence based antimicrobial therapy in CF can give some---but possibly limited---answers to this basal question. The objective of this systematic review is to summarize the available evidence on the use of antibiotics for the treatment of patients with CF infected by *P. aeruginosa*and *S. aureus* (MSSA, MRSA). We aim to include randomized trials (RCTS) mainly, but if we find no RCT for any of the outcome, we will discuss the observational studies.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Cystic Fibrosis Group and the Cochrane Infectious Diseases Group Specialized Registers, MEDLINE (1970 to June 2013). For MEDLINE search, following search terms were adopted: antibiotic route (*oral, intravenous OR nebulised OR inhaled OR aerosol*) *AND* antibacterial agents (*aztreonam OR tobramycin OR colistin or fluoroquinolones OR penicillin OR aminoglycoside OR glycopeptide OR cephalosporin*) AND (*cystic fibrosis*) AND infection (*pseudomonas OR Staphylococcus*) AND (*clinical trial, randomized controlled trial*) AND (*pneumonia OR lower respiratory tract infection*) AND (*child OR children OR infant OR paediatric OR pediatric OR adult*). Two independent reviewers reviewed the search results to identify relevant original human clinical trials. Additional studies were identified through manual searches of reference lists of the originally identified studies as well as reviews on the subject. No language restrictions were applied.

2.2. Study Selection {#sec2.2}
--------------------

Trials were selected if they used any route for administration of antibiotics for the eradication, prophylaxis, and/or treatment of either*P. aeruginosa*and/or *S. aureus*in patients with CF of any age and both sexes, treatment allocation was randomized or quasirandomized, and there was a control group (placebo or another inhaled antibiotic) and studied clinical (with or without microbiological) parameters. Trials only reporting microbiological parameters were excluded. In case there was no RCT for an important outcome, we considered observational studies if available.

2.3. Search Results {#sec2.3}
-------------------

A Cochrane Library (CENTRAL) search using the term "*antibiotics*" and filter "*Record Title*" yielded 26 Cochrane Systematic Reviews (CSR) and 1 protocol, 15 other (systematic) reviews, and 124 clinical trials. Simultaneous PUBMED search using the above search terms *yielded* 178 trials. Hand searching of the bibliography of relevant citations yielded an additional 32 papers that were retrieved and examined.

3. Results {#sec3}
==========

After applying above exclusion criteria (under study selection), removing the duplicates, and excluding review papers, 208 references were obtained. These were reviewed again in order to determine if they met the selection criteria. One hundred and seventy-four references were discarded: 77 were not randomized/quasirandomized (for an outcome with already existing RCTs), 38 on patients without CF, 21 substudies, 19 pharmacokinetic studies, 12 pharmacodynamic studies, 10 in vitro studies, and 7 pharmacoeconomic studies. Finally, 24 RCTs (*P. aeruginosa* = 21; *S. aureus* = 3), and 10 observational studies (*P. aeruginosa* = 3; *S. aureus* = 7) were included in the present review. Please also refer to Tables [1](#tab1){ref-type="table"}--[6](#tab6){ref-type="table"} for characteristics of the studies and summarization of key results. First, the antibiotic strategy about eradication of first or new airway colonization and treatment of chronically persistent airway colonization with *P. aeruginosa* will be discussed followed by the strategy for chronic suppressive therapy and eradication of *S. aureus* (both MSSA and MRSA).

3.1. *Pseudomonas aeruginosa* {#sec3.1}
-----------------------------

Individuals with cystic fibrosis (CF) whose respiratory tract is colonized with *P. aeruginosa* have as a group increased pulmonary disease, a more rapid decline in pulmonary function and a decreased survival to adulthood. Studies have shown that antibiotic therapy initiated shortly after a new detection of *P. aeruginosa*is effective in preventing or delaying the onset of chronic infection. Antibiotics administered via parenteral, inhaled, and oral routes are efficacious; however, the optimal regimen and duration of therapy remain unclear. Inhaled antibiotics are an attractive option, delivering high concentrations of antibiotic directly to the infection site while minimizing systemic exposure. In the present review, we will discuss evidence based antimicrobial therapy of *P. aeruginosa*in two parts: first part consisting of eradication of first or new air way colonization and the second part consisting of treatment of chronically persistent airway colonization.

3.2. Eradication of First or New Airway Colonization with *P. aeruginosa* {#sec3.2}
-------------------------------------------------------------------------

The effectiveness of the various antibioticregimes in eradicating early *P. aeruginosa* requires careful evaluation. There are many *P. aeruginosa* eradication protocols which utilize inhaled/nebulized or intravenous (iv) antipseudomonal antibiotics with or without oral antibiotics. These regimens are discussed below.

3.3. Tobramycin (Inhaled) versus Placebo or Other Antibiotics {#sec3.3}
-------------------------------------------------------------

A Cochrane review (CR) \[[@B2]\] including 2 RCTs \[[@B3], [@B4]\], and another new RCT \[[@B5]\] were analyzed. Evidence from two trials \[[@B3], [@B4]\] showed treatment of early *P. aeruginosa* infection with inhaled tobramycin results in microbiological eradication of theorganism from respiratory secretions more often than placebo (OR 0.15 (95% CI 0.03 to 0.65)) and that this effect may persist for up to 12 months. In a recent trial \[[@B5]\], 58 patients with median age of 9 years were randomized to treatment with tobramycin inhalation solution (TIS) for 28 days or inhaled sodium colistimethate (2 × 2 million units/d) plus oral ciprofloxacin (30 mg/kg/day) for 3 months (CC). The authors found no difference, and the two treatment groups resulted in similar eradication success at the end of treatment (80 and 90%, resp.) and similar clinical evolution during the first 2 years of follow-up.

In a cohort study \[[@B6]\], 15 patients (mean age 9 years) inhaled 80 mg tobramycin twice daily (BID) for 12 months. After 1 year, 14/15 was free from *P. aeruginosa*, and after 2 years, 9/15 had negative serum antibody titers against *P. aeruginosa*. There was an improvement in lung function noted before the intervention. In another cohort study \[[@B7]\], 36 young children treated with TSI (tobramycin solution for inhalation) 300 mg BID for 28 days or 56 days eradicated *P. aeruginosa* for up to 3 months after treatment.

There are three new trials \[[@B8]--[@B10]\] that were not included in the above CR. The ELITE trial \[[@B8]\] included 88 subjects and used microbiological (not clinical) criteria as the primary outcome. The authors found that treatment with TIS for 28 days is an effective and well-tolerated therapy in CF. The larger EPIC study \[[@B9]\] included 304 children. Participants randomized to cycled therapy received TIS for 28 days, with oral ciprofloxacin or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive *P. aeruginosa*cultures. There were no statistically significant differences in exacerbation rates between cycled and culture-based groups (hazard ratio (HR), 0.95; 95% CI, 0.54--1.66) or ciprofloxacin and placebo (HR, 1.45; 95% CI, 0.82--2.54). The odds ratio (OR) of *P. aeruginosa* positive culture comparing the cycled versus culture-based group was 0.78 (95% CI, 0.49--1.23) and 1.10 (95% CI, 0.71--1.71) comparing ciprofloxacin versus placebo. The Italian EPIC study \[[@B10]\] included 263 subjects to clarify the efficacy of two different eradication treatments, oral ciprofloxacin, and TIS (test treatment), compared with oral ciprofloxacin and inhaled colistin (reference treatment). Hundred five patients were assigned to inhaled colistin/oral ciprofloxacin (arm A) and 118 were assigned to inhaled tobramycin/oral ciprofloxacin (arm B). *P. aeruginosa* was eradicated in 66 (62.8%) patients in arm A and in 77 (65.2%) in arm B (OR 0.90, 95% CI 0.52 to 1.55). Following treatment, an increase in *S. maltophilia* was noted (OR 3.97, 95% CI 2.27 to 6.94) with no differences between the two arms (OR 0.89, 95% CI 0.44 to 1.78).

3.4. Colistin versus Placebo {#sec3.4}
----------------------------

We could identify one study \[[@B11]\]. This cohort study including very few patents (*N* = 7) with recent *P. aeruginosa*positive cultures used inhaled Colomycin 500,000 U BID and found a 36% reduction in the culture rate in long term.

3.5. Ciprofloxacin and Colistin versus Control {#sec3.5}
----------------------------------------------

One RCT \[[@B12]\] and three cohort studies \[[@B13]--[@B15]\] were included. The RCT by Valerius et al. \[[@B12]\] included 26 participants and used oral ciprofloxacin (250--750 mg BID) and inhalations of colistin (1 million units BID) for 3 weeks. During the 27 months of the trial, infection with *P. aeruginosa* became chronic in significantly fewer treated subjects than untreated subjects (14% versus 58%). Frederiksen et al. \[[@B13]\] included 91 participants and used oral ciprofloxacin (25--50 mg/kg/d) and inhalations of colistin (1 million units BID) for 3 weeks. The study was carried out over 44 months as only 16% of the treated patients developed chronic *P. aeruginosa* infection after 3(1/2) years compared with 72% of the control patients. Hansen et al. \[[@B14]\] included 146 patients and used oral ciprofloxacin (25--50 mg/kg/d) and inhalations of colistin (2 million units TID) for 3 months. A Kaplan Meyer plot showed protection from chronic infection in up to 80% of patients for up to 15 years. Treatment failure (*P. aeruginosa* positive culture immediately after the end of treatment of first ever isolate) was a strong risk factor for development of chronic infection after 3-4 years (odds ratio (OR) 5.8). Schelstraete et al. \[[@B15]\] included 41 patients and used oral ciprofloxacin (30 mg/kg/d) and inhalations of colistin (2 million units BID) for 3 months. Eleven patients became chronically colonized during the study period over 5 years.

3.6. Ciprofloxacin, Colistin, and Tobramycin versus Control {#sec3.6}
-----------------------------------------------------------

Vazquez et al. \[[@B16]\] included 16 patients and used oral ciprofloxacin (30--40 mg/kg/d) for 2 weeks, inhalations of colistin (1 million units), and inhaled tobramycin (100 mg BID) for long term. In follow-up, *P. aeruginosa* culture was positive in 4.6% of the treatment group compared to 86% of historic control group.

3.7. Intravenous (IV) Antibiotics with or without Inhaled and/or Oral Antibiotics {#sec3.7}
---------------------------------------------------------------------------------

In a pilot study \[[@B17]\] in 28 patients aged from 2 to 18 years, the authors gave a two-week course of azlocillin (150 mg/kg/d) and tobramycin (10--15 mg/kg/d). The eradication of *P. aeruginosa* that was achieved in 18 children was only temporary. Samples from only 10 and 5 patients remained negative 3 and 6 months after treatment, respectively. Only 5 children remained free from *P. aeruginosa* for a prolonged period from 14 to 32 months. Munck et al. \[[@B18]\] initiated treatment with a combination of IV ceftazidime (300 mg/kg/d) or imipenem (75 mg/kg/d) plus tobramycin (7.5 mg/kg/d) for 18--21 days, followed by nebulized colistin (1--3 million units) for \>2 months in 19 patients. Initial colonization was eradicated in all patients, but again all reacquired *P. aeruginosa* within 3--25 months during 3 years of follow-up. Griese et al. \[[@B19]\] included 17 patients and used inhaled tobramycin (80 mg BID) for 4 weeks in \<5 yrs and ciprofloxacin plus inhaled colistin (1 million units BID) for 3 weeks in \>5 yrs. In some patients, IV ceftazidime and tobramycin were also used. Initial *P. aeruginosa* colonization was successfully eradicated in 15 of 17 patients for at least two years. Nixon et al. \[[@B20]\] included 24 patients and used IV ticarcillin clavulanate plus tobramycin for 2 weeks, followed by oral ciprofloxacin or inhaled tobramycin for 3 months. Initial *P. aeruginosa* colonization was successfully eradicated in 25% patients only. Douglas et al. \[[@B21]\] included 26 patients and used IV ticarcillin clavulanate (300 mg/kg/d) or ceftazidime (150 mg/kg/d) plus IV tobramycin (7.5 mg/kg/d) for 2 weeks, followed by oral ciprofloxacin (10 mg/kg BID) and inhaled tobramycin (80 mg/kg BID) for 4 weeks. Initial *P. aeruginosa* colonization was successfully eradicated in 23 of 26 patients, and 3 of 23 patients developed recurrences after 1 year.

3.8. Treatment of Chronically Persistent Airway Colonization with *P. aeruginosa* {#sec3.8}
---------------------------------------------------------------------------------

It has been seen that the long-term effect on the prevalence ofchronic *P. aeruginosa* infection depends on the rate of acquisition of new infections,the efficiency of the eradication regime, that is, theclearance rate, as well as the time period free of *P. aeruginosa* after-treatment. Recent data shows that the effects of chronicinfection are more severe in those who acquired it at an earlier age \[[@B22]\]. There are many protocols which utilize inhaled/nebulized or oral or intravenous (i.v.) antipseudomonal antibiotics for treatment of chronic infection. These regimens are discussed below.

4. The Role of Inhaled Antibiotics {#sec4}
==================================

A Cochrane review studied the role of inhaled antibiotics for long-term suppression of chronic *P. aeruginosa* infection \[[@B23]\]. Seventeen trials including 1562 participants compared an inhaled antibiotic with placebo or usual treatment for a period of 1 and 32 months. Lung function (FEV1) was higher and exacerbations were less in the antibiotic-treated group. Resistance to antibiotics and minor side effects were more in the antibiotic-treated group.

4.1. Aztreonam Lysine (AZLI, Inhaled) versus Placebo {#sec4.1}
----------------------------------------------------

For more details, see [Table 1](#tab1){ref-type="table"}.

4.2. Aztreonam Lysine (AZLI, Inhaled) versus Tobramycin (Inhaled) {#sec4.2}
-----------------------------------------------------------------

An open label, parallel group trial compared AZLI and tobramycin nebulizer solution (TNS) in 273 patients (≥6 years) \[[@B29]\]. Patients were randomized to three 28-day courses (AZLI 75 mg TID or TNS 300 mg BD); 28 off-days separated each course. Mean baseline FEV1 was 52% predicted. Mean relative changes after 1 course (AZLI: 8.35%; TNS: 0.55%; *P* \< 0.001) and mean actual changes across 3 courses (AZLI: 2.05%; TNS: −0.66%; *P* = 0.002) indicated AZLI to be statistical superior over TNS. AZLI-treated patients had fewer respiratory hospitalizations (*P* = 0.044) and respiratory events requiring additional antibiotics (*P* = 0.004).

4.3. Tobramycin Inhaled versus Placebo {#sec4.3}
--------------------------------------

For more details, see [Table 2](#tab2){ref-type="table"}.

4.4. Fosfomycin/Tobramycin versus Placebo {#sec4.4}
-----------------------------------------

A single RCT evaluated fosfomycin/tobramycin for inhalation (FTI), 160/40 mg or 80/20 mg BID in 119 patients aged ≥18 years versus placebo, for 28 days \[[@B40]\]. The inclusion criteria were chronic *P. aeruginosa* infection and FEV1 25--75%. The authors found reduced rate of respiratory events (dyspnea and wheezing) more with FTI than placebo and more with an 80/20 mg dose of FTI than 160/40 mg dose. No clinically significant differences between groups were reported for laboratory values. FTI maintained the substantial improvements in FEV1% predicted and was well tolerated.

4.5. Tobramycin versus Colistin {#sec4.5}
-------------------------------

In a multicenter trial, 115 patients aged ≥6 years were randomised to receive either nebulized tobramycin (TNS) or colistin, BID for 4 weeks \[[@B41]\]. The primary end point was a change in FEV1% predicted. TNS produced a mean 6.7% improvement in lung function (*P* = 0.006), whilst there was no significant improvement in the colistin-treated patients (mean change 0.37%). In another randomized trial, 380 patients aged ≥6 years were randomised to Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1 662 500 IU, BID) or three 28-day cycles with BID 300 mg tobramycin (TIS) for 24 weeks \[[@B42]\]. The conclusion was that CDPI demonstrated efficacy by virtue of noninferiority to TIS in lung function after 24 weeks.

4.6. Colistin Inhaled versus Placebo {#sec4.6}
------------------------------------

For more details, see [Table 3](#tab3){ref-type="table"}.

4.7. Other Inhaled Antibiotics versus Placebo {#sec4.7}
---------------------------------------------

One RCT assessed the efficacy and safety of a novel aerosol formulation of levofloxacin (MP-376, Aeroquin) in 151 patients with CF with chronic *P. aeruginosa* infection \[[@B46]\]. The participants received one of three doses of MP-376 (120 mg OD, 240 mg OD, 240 mg BID) or placebo for 28 days. The authors found a dose-dependent increase in FEV1, with a difference of 8.7% between the 240 mg BID group and placebo (*P* = 0.003). Also a significant reduction (61--79%) in the need for other antimicrobials was observed with all MP-376 treatment groups. In a crossover study, the authors included 20 participants of 15--42 years age and administered carbenicillin (1 g) and gentamicin (80 mg) BID for 6 months \[[@B47]\]. Compared to placebo, improvement in lung function (FEV1, FVC, and PEF) was more and exacerbations of infection (courses of IV antibiotics) were less in treatment group. In another crossover study, the authors included 33 participants of  7.8--16 years age, and administered gentamicin (20 mg) BID for 12 months \[[@B48]\]. There was no significant difference in antibiotic usage, days in hospital or clinical symptoms between no treatment and treatment group, but subjects in treatment group with *P. aeruginosa* in sputum showed significantly less deterioration in lung function over 2 years. Yet, in another crossover design, the authors included 7 participants with mean age of 15.6 years and administered gentamicin (80 mg) TID for 3 months \[[@B49]\]. There was no significant difference in the lung function (FEV1, FVC) between the two groups.

A randomized crossover study compared three treatment groups: ceftazidime, gentamicin and carbenicillin, and saline, each given for 4 months \[[@B50]\]. There was significant improvement in the lung function (PEF, FEV1, and FVC) in both the treatment groups compared to the saline group, but there was no difference in the two treatment group.

5. The Role of Systemic Antibiotics {#sec5}
===================================

5.1. Oral Fluoroquinolones Compared to Placebo or Other Antibiotics {#sec5.1}
-------------------------------------------------------------------

In a RCT, 31 participants of  ≥18 years of age received ciprofloxacin or placebo for 10 days every 3 months for 1 year \[[@B51]\]. In the treatment group, patients reported a significant improvement in cough and PEF but not in the FEV1 and FVC. Also, there was no reduction in the hospital admissions or the number of courses of IV antibiotics.

In a randomized trial including participants of 8--25 years of age, 21 were randomly assigned to oral ciprofloxacin alone and 23 were randomly assigned to ciprofloxacin plus inhaled amikacin \[[@B52]\]. Continued improvement in clinical symptoms was observed in 14 patients in both treatment groups and the difference was not significant.

In a randomized crossover study 26 adult patients received ciprofloxacin 750 mg BID or ofloxacin 400 mg BID for 14 days, with three months washout period \[[@B53]\]. Treatment with both the drugs was associated with improvement in the clinical score, lung function tests, and inflammatory parameters; no difference between ciprofloxacin and ofloxacin was found.

In an open prospective clinical trial, the clinical efficacy of the conventional aminoglycoside plus beta-lactam treatment was compared to that of monotherapy with oral quinolones in 26 adult patients \[[@B54]\]. Six two-week courses of antipseudomonas treatment were administered with an interval of approximately three months between treatments. In each patient, two courses of conventional treatment were followed by two courses of quinolone treatment and then by other two courses of conventional treatment. The observed improvements in pulmonary function were somewhat higher when the patients received conventional treatments, and in the most seriously affected patients, conventional treatment was significantly better than quinolone treatment.

5.2. Azithromycin Compared to Placebo or Other Antibiotics {#sec5.2}
----------------------------------------------------------

For more details, see [Table 4](#tab4){ref-type="table"}.

5.3. Parenteral Antibiotics Compared {#sec5.3}
------------------------------------

Six children with *P. aeruginosa* isolated from their respiratory tract completed a randomized crossover study of oral flucloxacillin and nebulized aminoglycoside versus placebo \[[@B61]\]. The patients in the treatment group had higher FEV1 results at the end of the month of active treatment than placebo.

In a prospective multicenter interventional trial of iv meropenem (120 mg/kg/day) or iv ceftazidime (200--400 mg/kg/day), each administered together with iv tobramycin (9--12 mg/kg/day) and 78 patients were included for suppression therapy of chronic *P. aeruginosa* colonization \[[@B62]\]. Both treatments improved lung function, and no difference between treatment groups was observed.

5.4. *Staphylococcus aureus* {#sec5.4}
----------------------------

*S. aureus* is one of the first microbes and also one of the commonest to infect patients with cystic fibrosis. There has been an increase in the prevalence of colonization/infection with both methicillin-susceptible (MSSA) and methicillin resistant (MRSA) *S. aureus* over the past decade \[[@B63]\]. Colonization of the anterior nares with *S. aureus* represents an important risk factor for subsequent infection in both healthy and diseased population, but only few studies have investigated colonization in with CF. In one study, the authors reported a significantly increased prevalence among patients with CF who had not received anti-staphylococcal prophylaxis prior to taking the cultures \[[@B64]\]. Another study using nasal lavage found the presence of identical genotypes in upper and lower airways, which suggests that upper airways play a role as a reservoir of *S. aureus* (like *P. aeruginosa*) in CF \[[@B65]\]. In a 2-year cohort study of 100 children with CF, small-colony variants (SCVs) of *S. aureus* were detected among 24% of participants and were significantly associated with a greater drop in lung function during the study \[[@B66]\]. Other studies have also found SCVs to be associated with higher rates of antimicrobial resistance and more advanced lung disease \[[@B67]\]. We will discuss below the treatment (prophylactic and eradication) strategy for *S. aureus.*

5.5. Methicillin Sensitive *S. aureus* (MSSA) {#sec5.5}
---------------------------------------------

The approach for eradication of an initial infection and chronic suppressive treatment are different. In a retrospective cohort study, the authors enrolling 191 patients reported eradication of MSSA in 74% of the subjects after a single course of anti-staphylococcal antibiotics \[[@B68]\]. With continuing treatment, only 9% were found to be chronically infected over a six-month period, and on further follow-up, only a low level of resistance was found to anti-staphylococcal antibiotics \[[@B69]\]. Based on this, the European CF Consensus group has recommended initial 2--4 weeks of anti-staphylococcal antibiotic with new *S. aureus* infection \[[@B70]\]. However, the long-term results of such a approach are unknown and warrant further investigation.

Regarding the early chronic suppressive therapy, there have been many studies with variable results. These are summarized in [Table 5](#tab5){ref-type="table"}.

As it can be seen from the table, early chronic suppressive treatment of *S. aureus* has been associated with an increased infection with *P. aeruginosa* without any major clinical benefits. Same was the findings by the Cochrane review \[[@B76]\]. Though the US Guidelines do not recommend use of prophylactic anti-staphylococcal antibiotics as the UK and Australian guidelines, however, recommend flucloxacillin prophylaxis starting from the infancy \[[@B77]\].

Like treatment of *P. aeruginosa*with inhaled antibiotics, few studies have the role of inhaled antibiotics in the chronic treatment of MSSA infection. In one study, 13 patients (3--34 years) with chronic bronchopulmonary infection due to MSSA were treated with nebulized ampicillin (500 mg/12 h in those weighing \<40 kg and 1 g/12 h in those \>40 kg) over a period from 6 to 45 months (mean, 23 months) \[[@B78]\]. A significant reduction in the consumption of oral antibiotics (from 28 to 7 days/year) and number of hospitalizations (from 4 to 1/year) were observed. No significant differences were found for lung function, although it did not decline during the entire treatment period. Neither there was co-colonization due to *P. aeruginosa* nor was MSSA eradicated.

5.6. Methicillin Resistant *S. aureus* (MRSA) {#sec5.6}
---------------------------------------------

There are no current guidelines for treatment of MRSA in patients with CF. The prophylactic treatment has its own problem of emergence of antimicrobial resistance without any appreciable long-term effect. The treatment regimen differs depending upon whether outpatient or inpatient therapy is indicated. Drugs used for outpatient therapy include co-trimoxazole, minocycline (in children \> 8 years) and linezolid. If inpatient therapy is indicated, then iv vancomycin or teicoplanin are the drugs of choices. Recently, inhaled drugs like tobramycin/fosfomycin and inhaled vancomycin have been tried with some success \[[@B79]\].

Regarding the eradication protocol, there have been few uncontrolled studies done so far. These are summarized in [Table 6](#tab6){ref-type="table"}.

Though the concerns about MRSA and the success with early *P. aeruginosa* eradication have encouraged several centers to attempt eradication of MRSA, the long-term results are unknown. We need long-term controlled follow-up studies before any recommendations/guidelines can be made regarding the same.

6. Discussion {#sec6}
=============

6.1. Key Findings {#sec6.1}
-----------------

*P. aeruginosa* colonisation has a negative effect on lung function in patients with cystic fibrosis (CF). It is rather easy to eradicate the organism in the early stage of colonisation and to maintain a reduced bacterial density during chronic colonisation. For this, intermittent (few monthly) microbiological culture is advisable. Once the organism is isolated, the therapy depends upon presence or absence of symptoms. As a guide, the first isolation of *P. aeruginosa* without any clinical signs should be treated with oral ciprofloxacin plus inhaled aztreonam (AZLI) or colistin (COL) or tobramycin (TOB) (alternative being iv treatment with or without inhaled antibiotics) \[[@B85]\]. Reviewing the available data on the efficacy and safety of aztreonam (AZLI), colistin (COL), and tobramycin (TOB) administered by inhalation, we have discussed significant differences among these antibiotics. Inhaled antipseudomonal antibiotic treatment improves lung function. However, more evidence, from trials of longer duration, is needed to determine whether this benefit is maintained and to determine the significance of development of antibiotic-resistant organisms. Regarding the maintenance treatment of chronic *P. aeruginosa* infection/colonization, stable patients \> 6 years of age should be treated with any one of the inhaled antibiotics. For patients with development of mild symptoms, oral ciprofloxacin, and those with severe symptoms, intravenous antibiotics (preferably in combination) can be added \[[@B85]\]. Patients with highly resistant pathogens detected in sputum cultures may still derive clinical benefits from aerosolized antibiotics. This may be due to the substantial pharmacodynamic benefits of aerosolized antibiotics; that is, high concentrations of drug can be delivered to the site of infection with low risk of toxicity.

*S. aureus* is one of the earliest bacteria to be detected in infants and children with CF. The rise of MRSA in the last decade has caused a lot of attention to this organism, as the isolation of this organism has been associated with a decline in lung function. Similar to *P. aeruginosa*, many centers target this organism for aggressive treatment because of the negative impact on CF patients. As we have already discussed, there are many therapeutic options for both MSSA and MRSA. But many questions remain regarding the clinical utility and tradeoffs of prophylactic therapy for MSSA and eradication and treatment for MRSA. We also highlighted paucity of RCTs in the therapy of *S. aureus*. In order to advance the care of CF patients, controlled clinical trials are needed to find the optimal approach for managing CF patients who are infected with either MSSA or MRSA. But, currently no consensus exists regarding the same.

6.2. Limitations {#sec6.2}
----------------

A number of limitations apply to all the trials (mostly RCTs) included in this overview. First, most of the trials included relatively small numbers of patients, which lack of adequate power to prove the hypothesis (outcome measures). There is a probability of a type II error, simply because of the comparable study sizes and the limited number of studies, therefore population size under review. Second, not all trials are reported on each key outcome and outcomes are not reported in a consistent format.

6.3. Direction for Future Research {#sec6.3}
----------------------------------

As the inflammatory response of airways and the effect of inhaled antibiotics may not be the same in children and adults and many CF patients are surviving beyond adolescence, age-stratified analyses should be performed in future clinical trials. Increased availability of new inhaled antibiotics should also allow comparative trials to be performed between them. Though, assessment of pulmonary function (FEV1) is the common end point in many trials, quality of life (symptom score, medication score, and level of bother) should also bemeasured. Besides the standardtreatment regimen with 28-day on/28-day off cycles of inhaled antibiotics, feasibility of easier delivery schedules (such as 1 or 2 week on/off cycles or once daily dosing) should be investigated \[[@B86]\].

7. Conclusions {#sec7}
==============

As it is difficult to establish a firm recommendation based on the available evidence, the following factors must be considered for the choice of treatment for each patient: antibiotic related (e.g., safety and efficacy and ease of administration/delivery) and patient related factors (e.g., age, clinical status, prior use of antibiotics, coinfection by other organisms, and associated comorbidities).

###### 

Summary of AZLI trials.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                            Study design                                Subjects                                                                                                              Dose used                                         Outcomes                                               Main results
  --------------------------------- ------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------
  McCoy et al. \[[@B24]\]           Multicenter, RCT.                           *N* = 246.\                                                                                                           Aztreonam 75 mg for 4 weeks, BID or TID           Time to need for additional antibiotics, FEV1          Increased time to need for additional antibiotics, improved FEV1
                                                                                Age = \>6 years.\                                                                                                                                                                                                              
                                                                                Inclusion criteria: *P. aeruginosa*, 3 or more courses of tobramycin in previous year, FEV1 ≥25% and ≤75% predicted                                                                                                            

                                                                                                                                                                                                                                                                                                               

  Retsch-Bogart et al. \[[@B25]\]   Multicenter, RCT                            *N* = 105.\                                                                                                           Aztreonam 75 or 225 mg BID                        Percent change in FEV1 at end of 14 days               No significant change in FEV1, trend of greater improvement in lung function in those with worse baseline FEV1
                                                                                Age = \>13 years.\                                                                                                                                                                                                             
                                                                                Inclusion criteria: mild and moderate lung disease, and no recent use of antibiotics, FEV1 ≥40%                                                                                                                                

                                                                                                                                                                                                                                                                                                               

  Retsch-Bogart et al. \[[@B26]\]   Multicenter, RCT                            *N* = 164.\                                                                                                           Aztreonam 75 mg TID for 28 days                   Change in patient-reported respiratory symptom score   Significant improvement in self-reported symptom scores, improved FEV1
                                                                                Age = \>6 years.\                                                                                                                                                                                                              
                                                                                Inclusion criteria: moderate-to-severe lung disease, FEV1 ≥25% and ≤75% predicted                                                                                                                                              

                                                                                                                                                                                                                                                                                                               

  Oermann et al. \[[@B27]\]         Open label follow-up study over 18 months   *N* = 274.\                                                                                                           Dose used in the main trials \[[@B24], [@B27]\]   Safety and efficacy                                    Improved FEV1 and symptom scores, at the end of each cycle
                                                                                Age = \>8 years.\                                                                                                                                                                                                              
                                                                                Inclusion criteria: previous participant\                                                                                                                                                                                      
                                                                                in two other studies \[[@B24], [@B27]\]                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                               

  Wainwright et al. \[[@B28]\]      Multicenter, RCT                            *N* = 157.\                                                                                                           Aztreonam 75 mg TID for 28 days                   Change in patient-reported respiratory symptom score   No significant change in symptom score, improved FEV1
                                                                                Age = ≥6 years.\                                                                                                                                                                                                               
                                                                                Inclusion criteria: FEV1 \>75%                                                                                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of TIS/TSI trials.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Study design                   Subjects                                                                                                        Dose used                                                                                         Outcomes                                                                                                                            Main results
  ----------------------------- ------------------------------ --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Chuchalin et al. \[[@B30]\]   Multicenter, RCT               *N* = 247.\                                                                                                     Tobramycin 300 mg for 24 weeks                                                                    Percent change in FEV1, FVC, and FEF25--75%, pulmonary exacerbations, use of parenteral antibiotics, and rate of hospitalizations   Significantly improved FEV1, FVC, and FEF25--75%. The % of patients hospitalized as well as the need for parenteral antibiotics was significantly lower
                                                               Age = Adults.\                                                                                                                                                                                                                                                                                                                                        
                                                               Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Lenoir et al. \[[@B31]\]      RCT                            *N* = 59.\                                                                                                      Tobramycin 300 mg BID for 4 weeks                                                                 Percent change in FEV1, FVC, and FEF25--75%                                                                                         Significantly improved FEV1, FVC, and FEF25--75%
                                                               Age = 6--30 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                     

  MacLusky et al. \[[@B32]\]    RCT                            *N* = 28.\                                                                                                      Tobramycin 80 mg BID for 33 months                                                                Lung function (FEV1 and FVC), clinical scores, and exacerbations                                                                    The treatment group showed no change, while the control group had a significant decline in both pulmonary function and clinical status
                                                               Age = 7--24 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Murphy et al. \[[@B33]\]      Multicenter, RCT               *N* = 184.\                                                                                                     Tobramycin 300 mg BID, alternating 4-weekly cycles for 56 weeks                                   Lung function, hospitalisation, and antibiotic use                                                                                  Significant reductions in hospitalizations, antibiotic use, and a trend towards improvement in FEF25--75%
                                                               Age = 6--15 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: CF with mild lung disease                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Ramsey et al. \[[@B34]\]      Multicenter, Crossover study   *N* = 71.\                                                                                                      Tobramycin 600 mg TID for 4 weeks then crossover for two 28-day periods                           Lung function (FEV1, FVC, and FEF25--75%), exacerbations of infection and antibiotic use                                            Increase in the % change in FEV1, FVC, and FEF25--75%. Fewer exacerbations of infection and antibiotic use
                                                               Age = ≥6 years.\                                                                                                                                                                                                                                                                                                                                      
                                                               Inclusion criteria: chronic *P. aeruginosa* infection and FVC \>40%                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Ramsey et al. \[[@B35]\]      Multicenter, RCT               *N* = 520.\                                                                                                     Tobramycin 300 mg BID in three on-off cycles for a total of 24 weeks                              Lung function (FEV1 and FVC), exacerbations (hospitalization or IV antibiotics)                                                     Increase in the % change in FEV1 and FVC. Fewer hospitalizations and antibiotic use
                                                               Age = ≥6 years.\                                                                                                                                                                                                                                                                                                                                      
                                                               Inclusion criteria: chronic *P. aeruginosa* infection, FEV1 ≥25% and ≤75% predicted                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Moss \[[@B36]\]               Multicenter, RCT               *N* = 128.\                                                                                                     Tobramycin 300 mg in three 28-day cycles                                                          Pulmonary function, incidence of hospitalization, and IV antibiotic use                                                             Increase in the % change in FEV1. The average number of hospitalizations and IV antibiotic courses did not increase over time
                                                               Age = 13--17 years.\                                                                                                                                                                                                                                                                                                                                  
                                                               Inclusion criteria: chronic *P. aeruginosa* with mild-to-moderate lung disease (FEV1 ≥25% and ≤75% predicted)                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Stelmach et al. \[[@B37]\]    Observational study            *N* = 12.\                                                                                                      Tobramycin 300 mg in two 28-day cycles                                                            Pulmonary function, clinical status over 2-year period                                                                              Significant decline in lung function, clinical improvement
                                                               Age = 6--18 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: chronic *P. aeruginosa *infection with FEV1 ≥25% and ≤75% predicted                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Galeva et al. \[[@B38]\]      RCT                            *N* = 62.\                                                                                                      Tobramycin BID for one treatment cycle (18.5 days on drug, 28 days off drug)                      Change in FEV1%, quality of life                                                                                                    Change in FEV1%, quality of life
                                                               Age = 6--21 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: chronic *P. aeruginosa *infection and FEV1 ≥25% and ≤80% predicted                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                     

  Konstan et al. \[[@B39]\]     RCT                            *N* = 95.\                                                                                                      Tobramycin 112 mg BID for a total of three cycles (each cycle, 28 days on and 28 days off drug)   Change in FEV1%                                                                                                                     Increase in FEV1% along with decrease in the number of hospitalizations and antibiotic use
                                                               Age = 6--21 years.\                                                                                                                                                                                                                                                                                                                                   
                                                               Inclusion criteria: chronic *P. aeruginosa *infection and FEV1 ≥25% and ≤80% predicted                                                                                                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of inhaled colistin trials.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Study design        Subjects                                                Dose used                                                          Outcomes                                                                                  Main results
  ---------------------------- ------------------- ------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Jensen et al. \[[@B43]\]     RCT                 *N* = 40.\                                              Colistin (1 million units) BID for 3 months                        Lung function (FEV1 and FVC) and clinical score                                           Significant improvement in clinical symptom score and pulmonary function
                                                   Age = 7--35 years.\                                                                                                                                                                                                  
                                                   Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                

                                                                                                                                                                                                                                                                        

  Day et al. \[[@B44]\]        Crossover study     *N* = 14.\                                              Colistin (1 million units) BID for 3 months                        Lung function (FEV1 and FVC), antibiotic use and hospital admissions, and symptom score   Significantly improved FEV1, FVC. Decreased antibiotic use and hospitalization, and decreased symptom score
                                                   Age = 5--16 years.\                                                                                                                                                                                                  
                                                   Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                

                                                                                                                                                                                                                                                                        

  Nikonova et al. \[[@B45]\]   Prospective study   *N* = 2.\                                               Colistin (1 million units) BID for 3 weeks, followed till 1 year   Exacerbation rate, pulmonary symptoms                                                     Significant improvement in the symptoms and reduced exacerbation
                                                   Age = ≤5 years.\                                                                                                                                                                                                     
                                                   Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of azithromycin trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Study design       Subjects                                                                                                                             Dose used                                                                                                          Outcomes                                                                                      Main results
  ----------------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wolter et al. \[[@B55]\]      RCT                *N* = 60.\                                                                                                                           Azithromycin 250 mg OD for 3 months                                                                                \% change in FEV1 (FVC), weight, quality of life (QOL), respiratory\                          Improved QOL, reduced number of exacerbations, and reduced rate of decline in lung function
                                                   Age = 27.9 (±6.5) years.\                                                                                                                                                                                                                               exacerbations                                                                                 
                                                   Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                         

  Equi et al. \[[@B56]\]        Crossover study    *N* = 41.\                                                                                                                           Azithromycin 250 mg (500 mg if weight \>40 kg) OD for 6 months                                                     \% change in FEV1 (FVC and MEF), exercise tolerance, and subjective wellbeing                 FEV1 improved by ≥13% and fewer courses of antibiotics were required in the treatment group. Rest of other parameters did not improve.
                                                   Age = 8--18 years.\                                                                                                                                                                                                                                                                                                                                   
                                                   Inclusion criteria: chronic *P. aeruginosa* infection and with a median FEV1 of 61%                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                         

  Saiman et al. \[[@B57]\]      Multicenter, RCT   *N* = 185.\                                                                                                                          Azithromycin 250 mg (500 mg if weight \>40 kg) 3 days/week for 168 days                                            \% change in FEV1, weight, respiratory\                                                       Significant improvement in the FEV1%, weight, and reduced exacerbations
                                                   Age = ≥6 years.\                                                                                                                                                                                                                                        exacerbations                                                                                 
                                                   Inclusion criteria: FEV1 of ≥30%                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                         

  Clement et al. \[[@B58]\]     Multicenter, RCT   *N* = 82.\                                                                                                                           Azithromycin 250 mg (500 mg if weight \> 40 kg) 3 days/week for 12 months                                          \% change in FEV1 (FVC), weight, respiratory exacerbations, additional antibiotic treatment   FEV1% change did not differ significantly, but the numbers of pulmonary exacerbations and the additional courses of antibiotics were significantly reduced in the treatment group
                                                   Age = 6--21 years.\                                                                                                                                                                                                                                                                                                                                   
                                                   Inclusion criteria: FEV1 of ≥40%                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                         

  Steinkamp et al. \[[@B59]\]   Multicenter, RCT   *N* = 38.\                                                                                                                           Azithromycin (\<30 kg: 500 mg, 30--39 kg: 750 mg, 40--49 kg: 1000 mg, and ≥50 kg: 1250 mg) once/week for 8 weeks   \% change in FEV1 (FVC), weight, quality of life (QOL), respiratory\                          Pulmonary function declined in both the groups, but QOL was improved in the treatment group.
                                                   Age = 24.8 (±10) years.\                                                                                                                                                                                                                                exacerbations                                                                                 
                                                   Inclusion criteria: chronic *P. aeruginosa* infection                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                         

  Saiman et al. \[[@B60]\]      Multicenter, RCT   *N* = 260.\                                                                                                                          Azithromycin 250 mg (500 mg if weight \> 36 kg) 3 days/week for 6 months                                           \% change in FEV1, weight, respiratory\                                                       No significant change in the FEV1%, rate of hospitalizations, and use of additional antibiotics. But reduced exacerbations and increased weight in treatment group
                                                   Age = 6--18 years.\                                                                                                                                                                                                                                     Exacerbations, treatment requirements                                                         
                                                   Inclusion criteria: FEV1 of at least 50% predicted and negative respiratory tract cultures for *P. aeruginosa* for at least 1 year                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of studies on early chronic suppressive therapy of MSSA.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Study design        Subjects                                                                                                                                                        Drug used                                                                                                                                    Outcomes                                                                                         Main results
  ---------------------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Loening-Baucke et al. \[[@B71]\]   RCT                 *N* = 17.\                                                                                                                                                      Cephalexin                                                                                                                                   Clinical and microbiological                                                                     Significant improvement in clinical and microbiological parameters
                                                         Age = infants and children.\                                                                                                                                                                                                                                                                                                                                                                                  
                                                         Inclusion criteria: CF diagnosis                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Weaver et al. \[[@B72]\]           RCT                 *N* = 38.\                                                                                                                                                      Oral flucloxacillin 250 mg/day up to 2 years                                                                                                 Clinical and microbiological parameters, hospital admissions                                     More cough, greater numbers of *S aureus* isolates and increased hospitalization in the other (as required) group
                                                         Age = 7 weeks (prophylaxis group), 5 weeks for (as required group).\                                                                                                                                                                                                                                                                                                                                          
                                                         Inclusion criteria: CF diagnosis                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Nolan et al. \[[@B73]\]            Prospective study   *N* = 47.\                                                                                                                                                      Inhaled cephaloridine and oral cloxacillin in one group. Only oral cloxacillin in other groups                                               Number of respiratory tract infections or hospital admissions and change of pulmonary function   *Haemophilus influenzae* carriage was greater in the group not receiving inhaled antibiotic. High rates of carriage of *P. aeruginosa* and *P. cepacia* in both the groups
                                                         Age = children.\                                                                                                                                                                                                                                                                                                                                                                                              
                                                         Inclusion criteria: mild to moderate CF                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Ratjen et al. \[[@B74]\]           Prospective study   *N* = 639.\                                                                                                                                                     48.2% received continuous prophylaxis, 40.4% received intermittent, and 11.4% received no prophylaxis with anti-staphylococcal antibiotics   Number of respiratory tract infections                                                           Continuous prophylaxis group has a high rate of acquisition of *P. aeruginosa* than the other two groups
                                                         Age = \<18 year.\                                                                                                                                                                                                                                                                                                                                                                                             
                                                         Inclusion criteria: *P. aeruginosa* negative prior to entry and at least 2 additional *P*.* aeruginosa* negative respiratory cultures while being followed up                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Stutman et al. \[[@B75]\]          Multicentre,\       *N* = 119.\                                                                                                                                                     Oral cephalexin 80--100 mg/kg/day up to 5--7 years                                                                                           Clinical, microbiologic, laboratory, radiographic, and anthropometric outcomes                   Except an increased isolation of *P. aeruginosa*, there were no other benefits
                                     RCT                 Age = \<2 year\                                                                                                                                                                                                                                                                                                                                                                                               
                                                         Inclusion criteria: CF diagnosis                                                                                                                                                                                                                                                                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of trials for eradication of MRSA.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                          Study design        Subjects                                                              Drug used                                                                                                     Outcomes                                                                   Main results
  ------------------------------- ------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Solís et al. \[[@B80]\]         Retrospective       *N* = 12.\                                                            Continuous oral cephradine along with topical application of oral and nebulized vancomycin for 5 days         Microbiological and pulmonary function                                     MRSA was eradiated in 55%. FEV1 was not affected
                                                      Age (median) = 117 months.\                                                                                                                                                                                                                                    
                                                      Inclusion criteria: CF with chronic MRSA infection                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                     

  Macfarlane et al. \[[@B81]\]    Prospective         *N* = 17.\                                                            One five-day course of oral rifampicin and fusidic acid ± intravenous teicoplanin                             Microbiological                                                            MRSA was eradiated in 47% cases after the first course, in 71% after the second course, and in 94% when teicoplanin was added
                                                      Age = \<18 years Inclusion criteria: CF with chronic MRSA infection                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                     

  Garske et al. \[[@B82]\]        Prospective study   *N* = 7.\                                                             Rifampin and oral Fusidate for 6 months                                                                       Microbiological, use of iv antibiotics, and change of pulmonary function   MRSA was eradiated in 75%. Reduction in iv antibiotic use without any change in lung function
                                                      Age (mean) = 29.3 years.\                                                                                                                                                                                                                                      
                                                      Inclusion criteria: adult CF patients with chronic MRSA infection                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                     

  Halton et al. \[[@B83]\]        Prospective study   *N* = 17.\                                                            TMP-SMX (Trimethoprim-Sulfamethoxazole) for 4 weeks, mupirocin and rifampin in the last week over 18-months   Microbiological                                                            MRSA was eradiated in 60%
                                                      Age = \<18 year.\                                                                                                                                                                                                                                              
                                                      Inclusion criteria: CF with chronic MRSA infection                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                     

  Vanderhelst et al. \[[@B84]\]   Prospective study   *N* = 11.\                                                            Rifampin and oral Fusidate along with topical mupirocin for 6 months                                          Microbiological                                                            MRSA was eradiated in 100%
                                                      Age (median) = 9 years.\                                                                                                                                                                                                                                       
                                                      Inclusion criteria: CF with chronic MRSA infection                                                                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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